vs
Apellis Pharmaceuticals, Inc.（APLS）与Doximity, Inc.（DOCS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Doximity, Inc.的1.1倍（$199.9M vs $185.1M），Doximity, Inc.净利率更高（33.3% vs -29.5%，领先62.8%），Doximity, Inc.同比增速更快（9.8% vs -5.9%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
APLS vs DOCS — 直观对比
营收规模更大
APLS
是对方的1.1倍
$185.1M
营收增速更快
DOCS
高出15.7%
-5.9%
净利率更高
DOCS
高出62.8%
-29.5%
两年增速更快
DOCS
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $185.1M |
| 净利润 | $-59.0M | $61.6M |
| 毛利率 | — | 89.9% |
| 营业利润率 | -25.6% | 38.9% |
| 净利率 | -29.5% | 33.3% |
| 营收同比 | -5.9% | 9.8% |
| 净利润同比 | -62.2% | -18.1% |
| 每股收益（稀释后） | $-0.40 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSDOCS
| Q4 25 | $199.9M | $185.1M | ||
| Q3 25 | $458.6M | $168.5M | ||
| Q2 25 | $178.5M | $145.9M | ||
| Q1 25 | $166.8M | $138.3M | ||
| Q4 24 | $212.5M | $168.6M | ||
| Q3 24 | $196.8M | $136.8M | ||
| Q2 24 | $199.7M | $126.7M | ||
| Q1 24 | $172.3M | $118.1M |
净利润APLSDOCS
| Q4 25 | $-59.0M | $61.6M | ||
| Q3 25 | $215.7M | $62.1M | ||
| Q2 25 | $-42.2M | $53.3M | ||
| Q1 25 | $-92.2M | $62.5M | ||
| Q4 24 | $-36.4M | $75.2M | ||
| Q3 24 | $-57.4M | $44.2M | ||
| Q2 24 | $-37.7M | $41.4M | ||
| Q1 24 | $-66.4M | $40.6M |
毛利率APLSDOCS
| Q4 25 | — | 89.9% | ||
| Q3 25 | — | 90.3% | ||
| Q2 25 | — | 89.2% | ||
| Q1 25 | — | 89.5% | ||
| Q4 24 | — | 91.6% | ||
| Q3 24 | — | 90.0% | ||
| Q2 24 | — | 89.3% | ||
| Q1 24 | — | 89.4% |
营业利润率APLSDOCS
| Q4 25 | -25.6% | 38.9% | ||
| Q3 25 | 48.7% | 37.8% | ||
| Q2 25 | -18.6% | 37.4% | ||
| Q1 25 | -50.0% | 35.2% | ||
| Q4 24 | -12.3% | 47.4% | ||
| Q3 24 | -24.0% | 38.8% | ||
| Q2 24 | -14.7% | 36.4% | ||
| Q1 24 | -36.0% | 35.5% |
净利率APLSDOCS
| Q4 25 | -29.5% | 33.3% | ||
| Q3 25 | 47.0% | 36.8% | ||
| Q2 25 | -23.6% | 36.5% | ||
| Q1 25 | -55.3% | 45.2% | ||
| Q4 24 | -17.1% | 44.6% | ||
| Q3 24 | -29.2% | 32.3% | ||
| Q2 24 | -18.9% | 32.7% | ||
| Q1 24 | -38.5% | 34.4% |
每股收益（稀释后）APLSDOCS
| Q4 25 | $-0.40 | $0.31 | ||
| Q3 25 | $1.67 | $0.31 | ||
| Q2 25 | $-0.33 | $0.27 | ||
| Q1 25 | $-0.74 | $0.31 | ||
| Q4 24 | $-0.30 | $0.37 | ||
| Q3 24 | $-0.46 | $0.22 | ||
| Q2 24 | $-0.30 | $0.21 | ||
| Q1 24 | $-0.54 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $64.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $979.3M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSDOCS
| Q4 25 | $466.2M | $64.8M | ||
| Q3 25 | $479.2M | $169.2M | ||
| Q2 25 | $370.0M | $137.3M | ||
| Q1 25 | $358.4M | $209.6M | ||
| Q4 24 | $411.3M | $165.3M | ||
| Q3 24 | $396.9M | $184.2M | ||
| Q2 24 | $360.1M | $111.4M | ||
| Q1 24 | $325.9M | $96.8M |
总债务APLSDOCS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSDOCS
| Q4 25 | $370.1M | $979.3M | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.0B | ||
| Q1 25 | $164.2M | $1.1B | ||
| Q4 24 | $228.5M | $1.0B | ||
| Q3 24 | $237.1M | $961.2M | ||
| Q2 24 | $264.3M | $913.6M | ||
| Q1 24 | $266.7M | $901.4M |
总资产APLSDOCS
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | $1.3B | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $1.1B | ||
| Q2 24 | $904.5M | $1.1B | ||
| Q1 24 | $831.9M | $1.1B |
负债/权益比APLSDOCS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $60.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 0.99× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSDOCS
| Q4 25 | $-14.2M | $60.9M | ||
| Q3 25 | $108.5M | $93.9M | ||
| Q2 25 | $4.4M | $62.1M | ||
| Q1 25 | $-53.4M | $98.5M | ||
| Q4 24 | $19.4M | $65.2M | ||
| Q3 24 | $34.1M | $68.3M | ||
| Q2 24 | $-8.3M | $41.2M | ||
| Q1 24 | $-133.0M | $63.9M |
自由现金流APLSDOCS
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSDOCS
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSDOCS
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.2% | 0.0% |
现金转化率APLSDOCS
| Q4 25 | — | 0.99× | ||
| Q3 25 | 0.50× | 1.51× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | 1.58× | ||
| Q4 24 | — | 0.87× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | — | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
